Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.79 |
| ▸ | TDO2 | P48775 | 5/20 | 0.79 |
| ▸ | USP1 | O94782 | 1/20 | 0.45 |
| ▸ | USP19 | O94966 | 1/20 | 0.45 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7816954 | 0.89 | IDO1 (1.00) | IDO1TDO2PTGS2KDM4EALDH1A1 | |
| SCHEMBL22732884 | 0.88 | IDO1 (0.63) | IDO1TDO2PTGS2KDM4EPOLB | |
| SCHEMBL7805767 | 0.87 | IDO1 (0.71) | IDO1TDO2USP1USP19PTGS2 | |
| SCHEMBL7805662 | 0.85 | IDO1 (0.60) | IDO1TDO2PTGS2PTGDR2MEN1 | |
| SCHEMBL7805861 | 0.85 | IDO1 (0.60) | IDO1TDO2PTGS2PTGDR2MEN1 | |
| SCHEMBL7805807 | 0.85 | IDO1 (0.60) | IDO1TDO2PTGS2KDM4EPTGDR2 | |
| SCHEMBL7808005 | 0.85 | IDO1 (0.60) | IDO1TDO2PTGS2KDM4EPTGDR2 | |
| SCHEMBL7812685 | 0.85 | IDO1 (0.72) | IDO1TDO2USP1PTGS2KDM4E | |
| SCHEMBL8595445 | 0.85 | IDO1 (0.82) | IDO1TDO2MEN1KMT2A | |
| SCHEMBL7805716 | 0.84 | IDO1 (0.62) | IDO1TDO2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450281-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-0876356-B1 | USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF | INNOTHERA SA LAB (FR) | 2001-10-31 | — | — | EP | disclosed |
| US-6262095-B1 | TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA | LABORATOIRE INNOTHERA (FR) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450281-B1 | Compounds and methods for treating cancer | USP8, USP2, NEDD8 | IDO1 2561/4885TDO2 2554/4885USP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.